Get the Daily Brief
Latest Biotech News
Earendil Labs raises $787M — AI platform scales drug pipeline
Earendil Labs announced a $787 million private financing to expand an AI-driven drug discovery platform that the company says has produced more than 40 programs. The funding positions Earendil to...
Verily raises $300M: Alphabet loses majority control
Verily secured $300 million in outside capital that ends Alphabet’s controlling stake in the healthcare innovation company, the firm announced. The financing—led by Series X Capital with other...
Abbott closes $23B Exact Sciences buy — Diagnostics becomes core growth play
Abbott announced completion of its $23 billion acquisition of Exact Sciences after regulatory clearances, folding Cologuard, Oncotype DX and other cancer‑screening assays into Abbott’s diagnostics...
Novartis pays $2B upfront — Next‑gen PI3Kα joins breast cancer arsenal
Novartis agreed to pay $2 billion upfront to acquire an experimental, pan‑mutant‑selective PI3Kα inhibitor from Synnovation Therapeutics, aiming to bolster or defend its breast‑cancer franchise....
Roche and Genentech abandon muscle‑building programs — Trials fail to show benefit
Roche confirmed it is halting development of emugrobart after a key study failed to show consistent improvements in muscle growth and motor function, notifying European patient communities....
Lilly’s triple‑agonist retatrutide clears Phase III A1C and weight endpoints
Eli Lilly reported positive top‑line Phase III results for retatrutide, a GIP/GLP‑1/glucagon ‘triple’ agonist, showing significant A1C reductions and substantial weight loss in people with type 2...
FDA clears high‑dose Wegovy fast — Commissioner’s voucher accelerates review
The FDA approved a 7.2 mg high‑dose formulation of Novo Nordisk’s Wegovy under a commissioner’s voucher program that compressed review to roughly two months. Novo said the higher‑dose injectable...
FDA and NIH push to pare animal testing — Draft guidance issued
The FDA and NIH published draft guidance and policy moves aimed at validating non‑animal 'new approach methodologies' (NAMs) for toxicology and early safety studies, signaling a regulatory shift...
In vivo CAR‑T edges closer — Precision engineering generates CAR T inside patients
Two independent research teams reported advances toward generating CAR‑T cells in vivo, demonstrating programmable, site‑specific integration or dual‑vector approaches that reprogram T cells...
Pelareorep wins FDA fast track — Oncolytic virus targets KRAS‑mutant colorectal cancer
Oncolytics Biotech said the FDA granted Fast Track designation to pelareorep (Reolysin) in combination with bevacizumab and FOLFIRI for second‑line treatment of KRAS‑mutant, microsatellite‑stable...
Abbott to close $23 billion Exact Sciences deal Monday – Enters cancer‑screening market
Abbott announced the scheduled close of its $23 billion acquisition of Exact Sciences after receiving final regulatory clearances. The deal brings Cologuard, Oncotype DX, Oncodetect and...
Novartis pays $2B upfront for next‑gen PI3Kα – Rivalry around breast‑cancer franchise intensifies
Novartis agreed to a deal that pays Synnovation roughly $2 billion upfront for a pan‑mutant‑selective PI3Kα inhibitor aimed at breast cancer. The acquisition targets a next‑generation molecule...
Lilly’s triple‑agonist retatrutide wins Phase III endpoints – Major A1C and weight gains reported
Eli Lilly reported positive top‑line results from Transcend‑T2D‑1: the triple‑agonist retatrutide produced clinically meaningful A1C reductions and substantial weight loss in people with type 2...
FDA widens rare‑obesity label; J&J gets oral IL‑23 pill — regulators clear niche and mainstream drugs
The FDA expanded the label for Rhythm Pharmaceuticals’ Imcivree to include adults and children aged 4 and up with acquired hypothalamic obesity, making it the first approved therapy for that...
CAR‑T made inside the patient: Dual‑vector in vivo integration shows tumor clearance in preclinical models
Researchers at UCSF reported a dual‑vector approach that enables programmable, site‑specific integration of large DNA payloads into T cells in vivo, producing functional CAR‑T cells without ex...
Generalist biological AI... and a trillion‑gene push: Big data meets drug design
Nature Biotechnology published a review mapping a vision for generalist biological AI—models capable of performing diverse tasks across biological domains rather than narrow, single‑use tools. The...
AstraZeneca doubles down on China: Cell‑therapy R&D and manufacturing hub goes ahead
AstraZeneca revealed plans to build an end‑to‑end cell‑therapy R&D and manufacturing base in Shanghai and to establish an innovation center with early‑stage research and regulatory support. The...
Decentralized diagnostics: Diasorin distribution deal and WHO’s new TB nPOC‑NAAT class
Diasorin signed a distribution agreement with McKesson Medical Surgical to push its Liaison Nes point‑of‑care PCR system into non‑acute settings, including physician office labs and decentralized...
Congress revives SBIR/STTR seed funding – Biotech early‑stage lifeline restored
Congress reauthorized the SBIR and STTR programs, restoring federal seed funding for small businesses and research teams after a lapse. The bipartisan action preserves critical early‑stage grant...
Congruence raises fresh capital as it starts human trials – Protein‑misfolding correctors advance
Congruence Therapeutics closed a $39.5 million financing round to advance a portfolio of small‑molecule correctors targeting protein‑misfolding diseases into the clinic. The funding follows the...